U.S. Blood Growth Factors Markets : Market Research Report

1. Executive Summary

2. Total Market
1. Report Scope and Segmentation
1. Research Scope and Segmentation
2. Market Overview
1. Introduction
2. Market Engineering Analysis
3. Market Demand and Forecasts
1. Demand Analysis
2. Market Forecasts
4. Industry Issues and Challenges
1. Challenges
a. Lack of Homogeneity in Clinical Trials due to the Nascent Stage of the Growth Factors Market is likely to Set Back the Time to Market of Promising Growth Factors
b. The Existence of Competing Treatment and Cheaper Standards of Care Threatens the Market Potential for Growth Factors
c. The Fact that Growth Factors can Stimulate Tumor Growth Poses Challenges in Securing FDA Approval for Newer Drugs
d. Reimbursement for Blood Growth Factors is a Key Impeding Factor for the Growth of Blood Growth Factors
e. The Industry-wide Inconsistency in Definitions for Abnormal Levels of Blood Cells, which are Used to Gauge Disease, is likely to Limit the Market Potential of Blood Growth Factors
5. Pipeline Analysis
1. Products in the Pipeline
6. Frost & Sullivan Awards
1. Market Leadership Award
2. Product Leadership Award
3. Customer Service Innovation
4. Technology Excellence Award

3. Erythropoietins Market
1. Overview
1. Introduction
2. Market Engineering Analysis
2. Market Analysis and Forecasts
1. Demand Analysis
2. Revenue Forecasts
3. Market Drivers
a. Innovations and Improvements in the Drug Delivery Technologies Augment the Market Potential for Blood Growth Factors
b. Growth in the Aging Population Increases the Prevalence of Kidney Disorders and Cancers, which Drive the Uptake of Erythropoietins
4. Market Restraints
a. Competition with Generic Drug Manufacturers After the Expiry of Key Patents on some Blood Growth Factors is likely to Impact Revenues
b. Fluctuating Chemotherapy and Dialysis Treatment Usage Patterns may Negatively Affect the Demand for Blood Growth Factors
5. Competitive Structure

4. Colony Stimulating Factor Market
1. Overview
1. Introduction
2. Market Engineering Analysis
2. Market Analysis and Forecasts
1. Demand Analysis
2. Revenue Forecasts
3. Market Drivers
a. Substitution for the Number of Blood Transfusions Required Drives the Popularity and Acceptance of Blood Growth Factors
b. Growing Population on Chemotherapy Increases the Market Demand for Colony Stimulating Factors
4. Market Restraints
a. Competition Between Generic Drug Manufacturers After the Expiry of Key Patents on Some Blood Growth Factors is likely to Impact Revenues
b. Colony Stimulating Factor Treatment is Dependent on Chemotherapy. Any Change in the Demand for Chemotherapy shall impact the CSF Revenues
5. Competitive Structure

5. Interferons Market
1. Overview
1. Introduction
2. Market Engineering Analysis
2. Market Analysis and Forecasts
1. Demand Analysis
2. Revenue Forecasts
3. Market Drivers
a. Huge Number of Cancer and Hepatitis Patients Spurs Revenues
b. Investment Gains Encourage Companies to Research New Areas
c. Aging of Baby Boomers Bolsters Patient Population
4. Market Restraints
a. Side Effect Profile Limits Usage of Interferon
b. Reimbursement Issues Affect Profitability
c. Fierce Competition Confines Market Revenues
d. Regulatory Problems Curb Revenues
5. Competitive Structure

6. Interleukins Market
1. Overview
1. Introduction
2. Market Engineering Analysis
2. Market Analysis and Forecasts
1. Demand Analysis
2. Revenue Forecasts
3. Market Drivers
a. Prevalence and Incidence of Cancers of Kidney and Melanoma Act as Key Driver for Interleukins
b. Investor interest in companies focusing on newer technology drives companies to research new areas
c. Aging of Baby Boomers Bolsters Patient Population
4. Market Restraints
a. Obtaining a Greater Therapeutic Index Restricts Revenue Realization
b. Delay in FDA Approvals Poses Challenge to Revenue Realization
c. Difficulty in Raising Funds is likely to Cause Delay in Conduction of Trials, Leading to Delay in Revenue Generation
5. Competitive Structure

7. Appendix
1. Decision Support Databases
1. Total Healthcare Expenditure
2. Population over 65 Years
3. Hospitals
4. Hospital Beds
5. Nervous Sense Organs and Mental Disorders Mortality

Abstract

Skepticism in the Medical Community Regarding the Safety of Blood Growth Factors Limits Market Growth

Unfamiliarity of the healthcare community with blood growth factors is proving to be a major hurdle in achieving their full potential. Medical personnel usually possess a sound background in small protein therapy but are not open to the idea of using larger protein molecules for treatment. In addition, government agencies and private organizations frequently publish influential guidelines or recommendations to healthcare providers that are likely to limit the usage of blood growth factors. Ultimately, the success of blood growth factors lies in positioning and highlighting the product attributes and benefits. For instance, while blood transfusion is a time-tested procedure for treating anemia, it is expensive, painful, and increases the risk of contracting fatal diseases. Growth factor therapies, on the other hand, are several times safer and more dependable.

This Frost & Sullivan research analysis evaluates the latest developments in the blood growth factors market. In addition to analyzing the key drivers and challenges, this study also discusses the standard therapies and emerging treatments for the erythropoietin (EPO), colony stimulating factors, interferons, and interleukins market segments.

Innovations and Improvements in Drug Delivery Technologies Augment the Demand for Blood Growth Factors

Blood growth factor developers are leveraging the benefits provided by second-generation products to widen the application scope and market potential of their therapies. "Besides providing greater patent protection for the original drug, second-generation products offer a competitive advantage over current marketed products by utilizing drug delivery technologies to offer value-added treatments," explains the analyst.

A good example is Amgen’s Aranesp, which is a longer-lasting version of the company’s EPO product. Before Aranesp, the only alternative to EPO was a blood transfusion that was not only expensive and painful but also put the patient at the risk of contracting other diseases such as HIV. Aranesp scores over both blood transfusions and regular EPO treatment by changing the dosage schedule from three times to once a week and improving the quality of life for dialysis patients.

Gaining the approval of the Food and Drug Administration (FDA) can prove to be a daunting task. "However, blood growth factors that could potentially stimulate tumor growth face greater challenges in receiving FDA approval," notes the analyst. Some growth factors such as Epogen, Neupogen, and Cytokine have already received the green signal from the FDA but must carry a label informing patients of their potential dangers. Such labels influence the prescribing behavior of physicians and hence, limit the reach of blood growth factors.

Blood growth factor developers need to improve the side-effect profile of their formulations to accelerate FDA approval and expand market opportunity. However, they must understand that approval does not necessarily guarantee commercial success. In some instances, general usage or post-marketing studies reveal safety or other previously unknown problems that are likely to suspend or revoke regulatory approvals.

U.S. Blood Growth Factors Markets

Table of Contents

Abstract